Oncopeptides AB (publ) (LON:0RN4)

Market Cap	24.09M
Revenue (ttm)	1.99M
Net Income (ttm)	-20.77M
Shares Out	n/a
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,349
Open	n/a
Previous Close	1.480
Day's Range	n/a
52-Week Range	0.108 - 0.565
Beta	n/a
RSI	48.35
Earnings Date	Feb 21, 2025

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 57
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RN4

Financial Performance

In 2023, Oncopeptides AB's revenue was 35.22 million, an increase of 321.54% compared to the previous year's 8.36 million. Losses were -249.11 million, -26.29% less than in 2022.

Financial numbers in SEK